- Home
- TLSI vs TARA Comparison
TLSI vs TARA Comparison
Compare TLSI & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- TARA
- Stock Information
- Founded
- TLSI 2010
- TARA N/A
- Country
- TLSI United States
- TARA United States
- Employees
- TLSI N/A
- TARA N/A
- Industry
- TLSI Medical Specialities
- TARA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TLSI Health Care
- TARA Health Care
- Exchange
- TLSI Nasdaq
- TARA Nasdaq
- Market Cap
- TLSI 160.4M
- TARA 136.3M
- IPO Year
- TLSI N/A
- TARA N/A
- Fundamental
- Price
- TLSI $5.62
- TARA $4.58
- Analyst Decision
- TLSI Strong Buy
- TARA Strong Buy
- Analyst Count
- TLSI 6
- TARA 4
- Target Price
- TLSI $11.75
- TARA $22.67
- AVG Volume (30 Days)
- TLSI 66.8K
- TARA 212.8K
- Earning Date
- TLSI 03-27-2025
- TARA 03-05-2025
- Dividend Yield
- TLSI N/A
- TARA N/A
- EPS Growth
- TLSI N/A
- TARA N/A
- EPS
- TLSI N/A
- TARA N/A
- Revenue
- TLSI $29,431,000.00
- TARA N/A
- Revenue This Year
- TLSI $55.43
- TARA N/A
- Revenue Next Year
- TLSI $50.09
- TARA N/A
- P/E Ratio
- TLSI N/A
- TARA N/A
- Revenue Growth
- TLSI 58.99
- TARA N/A
- 52 Week Low
- TLSI $3.50
- TARA $1.60
- 52 Week High
- TLSI $10.42
- TARA $10.48
- Technical
- Relative Strength Index (RSI)
- TLSI 55.78
- TARA 57.21
- Support Level
- TLSI $5.06
- TARA $4.41
- Resistance Level
- TLSI $5.72
- TARA $4.81
- Average True Range (ATR)
- TLSI 0.37
- TARA 0.27
- MACD
- TLSI 0.03
- TARA 0.06
- Stochastic Oscillator
- TLSI 90.65
- TARA 78.01
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).